Last Updated: September 24, 2026

Details for Patent: 10,961,522


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,961,522 protect, and when does it expire?

Patent 10,961,522 protects OPFOLDA and is included in one NDA.

This patent has ninety-four patent family members in forty-three countries.

Summary for Patent: 10,961,522
Title:Highly potent acid alpha-glucosidase with enhanced carbohydrates
Abstract:Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.
Inventor(s):Russell Gotschall, Hung V. Do
Assignee: Amicus Therapeutics Inc
Application Number:US16/252,505
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,961,522

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Therap Us OPFOLDA miglustat CAPSULE;ORAL 215211-001 Sep 28, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial THE TREATMENT OF POMPE PATIENTS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,961,522

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3201320 ⤷  Start Trial 301267 Netherlands ⤷  Start Trial
European Patent Office 3201320 ⤷  Start Trial LUC00336 Luxembourg ⤷  Start Trial
European Patent Office 3201320 ⤷  Start Trial CA 2024 00012 Denmark ⤷  Start Trial
European Patent Office 3201320 ⤷  Start Trial PA2024509 Lithuania ⤷  Start Trial
European Patent Office 3201320 ⤷  Start Trial 2024C/513 Belgium ⤷  Start Trial
European Patent Office 3201320 ⤷  Start Trial 122024000016 Germany ⤷  Start Trial
European Patent Office 3201320 ⤷  Start Trial C20240010 Finland ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.